NanoViricides' President Discusses New HIV Drugs and Company Goals in Interview with NanoBiotech News
Thursday July 21, 8:53 am ET
Provides In-Depth Interview of the NanoViricides Story
NEW YORK--(BUSINESS WIRE)--July 21, 2005--NanoViricides, Inc. (Pink Sheets:NNVC - News), has announced the online availability of a feature article about NanoViricides, Inc. in the July 13, 2005 edition of NanoBiotech News. In the article, Dr. Diwan discusses NanoViricides' uniqueness and drug development goals as it prepares to compete in the multi-billion-dollar bio-pharmaceutical marketplace.
The article can be viewed free of charge by visiting nanoviricides.com
[[ARTICLE here: nanoviricides.com ]]
Information about NanoBiotech News can be found at nanobiotechnews.com
About NanoViricides - nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and anticipates that it will license the products to major pharmaceutical companies.
This press release contains forward-looking statements which reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
--------------------------------------------------------------------------------
Contact:
NanoViricides, Inc., New York
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
or
Anil R. Diwan, Ph.D.
adiwan@snet.net
--------------------------------------------------------------------------------
Source: NanoViricides, Inc.
biz.yahoo.com |
